B+
Bull case
25%
Probability
Target price
$36.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
RCUS
Arcus BiosciencesBNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$28.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$17.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-05-08
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+75.0
Score
AI commentary
This remains a cautious monitoring setup. The key new evidence on May 5, 2026 came from company materials rather than broad analyst digestion: the earnings release and 8-K confirmed a stronger runway and a clearer casdatifan-first plan, but also a narrower portfolio after STAR-121. Immediate market reaction appears muted rather than thesis-changing, and by May 8, 2026 visible post-print analyst revision evidence was still thin, so confidence should stay moderate rather than bullishly upgraded. [#8-K-2026-05-05][#10-Q-2026-05-05]
RankAlpha Sentiment Codex - 2026-05-08
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-05catalystQ1 earnings reset preserved runway but confirmed a narrower, casdatifan-led storyMedium impact
The May 5, 2026 earnings release confirmed $876 million of cash and marketable securities, runway into at least the second half of 2028, expected R&D relief from winding down domvanalimab studies, and a sharper capital focus on casdatifan. That reduces near-term financing risk, but it does not by itself create a new upside leg without later clinical proof. [#8-K-2026-05-05][#10-Q-2026-05-05]
2026-09-30eventMultiple 2026 casdatifan readouts now carry most of the rerating burdenHigh impact
Arcus guided to 2026 data from ARC-20, including more mature overall response and initial progression-free-survival data for casdatifan plus cabozantinib in IO-experienced ccRCC, initial early-line cohort data, and updated late-line monotherapy results. With domvanalimab de-emphasized after STAR-121 was stopped for futility, these readouts are now the main stock-moving proof points. [#8-K-2026-05-05]
2026-12-31catalystPEAK-1 enrollment completion and a first-line Phase 3 start by year-end would strengthen the RCC backbone thesisHigh impact
Management said PEAK-1 enrollment is accelerating and that both PEAK-1 enrollment completion and initiation of a first-line Phase 3 study are expected by year-end 2026. Hitting those milestones would show execution against the post-TIGIT reset plan, but failure would reinforce that the investment case is overly concentrated in one franchise. [#8-K-2026-05-05]
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-08 • Updated nightlySource: Internal modelMethodology